IceCure Medical Ltd. (ICCM), on Tuesday, appointed Meir Peleg as Chief Financial Officer, effective May 17.
Peleg brings over 20 years of financial leadership experience, including roles at Nasdaq-listed companies.
The appointment comes as the company gains momentum following U.S. FDA clearance for ProSense in low-risk breast cancer and a recommendation from the American Society of Breast Surgeons.
Further, the company intends to appoint Richard Fine as Medical Director in the second quarter of 2026 to support its breast cancer clinical and educational initiatives.
Vice President of R&D and Engineering Naum Muchnik will depart effective April 12, as the company initiates a search for a new Chief Technology Officer.
In the pre-market trading, IceCure Medical is 6.67% higher at $0.6800 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.